Hologic’s (HOLX) “Buy” Rating Reiterated at BTIG Research
BTIG Research reaffirmed their buy rating on shares of Hologic (NASDAQ:HOLX) in a report published on Wednesday, The Fly reports. The firm currently has a $84.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $63.00.
HOLX has been the topic of a number of other reports. Wells Fargo & Co increased their price objective on Hologic from $48.00 to $60.00 and gave the company an overweight rating in a research report on Thursday, April 30th. Cowen upgraded Hologic from a market perform rating to an outperform rating and set a $64.00 price objective on the stock in a research report on Tuesday, June 30th. Zacks Investment Research lowered Hologic from a hold rating to a sell rating and set a $52.00 price objective on the stock. in a research report on Tuesday, April 28th. Needham & Company LLC started coverage on Hologic in a research report on Wednesday, July 1st. They issued a buy rating and a $64.00 price objective on the stock. Finally, Stifel Nicolaus decreased their price objective on Hologic from $52.00 to $45.00 and set a hold rating on the stock in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. Hologic has an average rating of Buy and a consensus price target of $65.38.
NASDAQ HOLX opened at $69.78 on Wednesday. The firm has a market cap of $18.05 billion, a PE ratio of 28.25, a price-to-earnings-growth ratio of 3.69 and a beta of 1.47. Hologic has a one year low of $26.49 and a one year high of $70.35. The stock’s 50 day simple moving average is $57.42 and its 200 day simple moving average is $50.06. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.47 and a quick ratio of 1.04.
In related news, insider Peter J. Valenti III sold 10,493 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $51.82, for a total transaction of $543,747.26. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Stephen P. Macmillan sold 190,996 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $50.97, for a total value of $9,735,066.12. The disclosure for this sale can be found here. Insiders have sold a total of 243,932 shares of company stock worth $12,507,250 in the last ninety days. 1.00% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cornerstone Advisors Inc. raised its stake in shares of Hologic by 202.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 447 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 299 shares during the period. Sunbelt Securities Inc. acquired a new stake in shares of Hologic in the 4th quarter valued at about $6,526,000. Signaturefd LLC raised its stake in shares of Hologic by 67.4% in the 1st quarter. Signaturefd LLC now owns 792 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 319 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in shares of Hologic in the 4th quarter valued at about $45,000. Finally, CWM LLC raised its stake in shares of Hologic by 63.4% in the 1st quarter. CWM LLC now owns 910 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 353 shares during the period. 92.34% of the stock is currently owned by hedge funds and other institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: Do stock splits help investors?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.